Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 October 2021 | Story Lunga Luthuli and Vicky Simpson | Photo Supplied
Anton Engelbrecht _ Farmovs researcher
Anton Engelbrecht, FARMOVS Bioanalysis Specialist.

“At FARMOVS, we have the opportunity to work with the world’s top pharmaceutical companies, where we form part of the evaluation of labelled and/or conjugated antigens and antibodies that are developed for accurate quantification of endogenous and pharmaceutical compounds. Alternatively, commercially available kits and reagents are also used for the same purpose if the sponsor cannot supply the customised antigens/antibodies. The developed assay methods are put through a rigorous validation assessment to confirm the selectivity, sensitivity, and robustness of the assay,” says Anton Engelbrecht, FARMOVS Bioanalysis Specialist. 

FARMOVS, affiliated to the University of the Free State and operating from the Bloemfontein Campus, is a leading clinical research organisation (CRO) with a unique advantage. As the only on-site ISO15189-accredited and GLP-certified pharmacokinetic laboratory on the African continent, with numerous successful inspections by leading international regulators, it offers the highest quality bioanalytical services in a variety of biological matrices for the development of pharmaceutical products.

Engelbrecht says: “The team of bioanalytical experts thrives on the excitement generated by new discoveries that lead to better treatment of a variety of physiological diseases.”

Advanced technology backed by 47 years of bioanalytical experience

The clinical research organisation prides itself on advanced technology, backed by 47 years of bioanalytical experience. It has developed more than 580 validated analytical methods that adhere to the International Council for Harmonisation and the US Food and Drug Administration (FDA) guidelines. FARMOVS’ analytical methods have been used in more than 3 000 pre-clinical and clinical trials, contributing to the manufacturing of pharmaceutical drugs that are now used by households across the globe.

At FARMOVS, Engelbrecht says, it is a “world filled with novel methods of analysis and subsequent technological integration that expands the horizons of clinical research forming an important part of the discovery and production of new life-saving medicines that is constantly improving the quality of life of people all over the world”.

Engelbrecht says: “New technology and innovation should be the building blocks of any laboratory, and among these are the three fastest sample production members of our Immunochemistry Laboratory team – the STARLet pipettors.”

“We chose the Microlab® STARLet apparatus by Hamilton, because of its ability to perform sample analysis in large quantities at a greater speed by means of robotic pipetting and robotic automated microplate reading, which is a semi-automated process.”

He shared his excitement about improvements in the field of immunoassay development for the purposes of pharmaceutical analysis. This involves the preparation of unique immunoanalytical reagents, analysis of new categories of compounds, methodology, and instrumentation. The most important examples in this field are the continuous development of bead-based immunoassays.

Staying competitive in the industry

Immunoassay methods, such as radioimmunoassay (RIA) and enzyme immunoassay (EIA), among others, are also used at FARMOVS to analyse macromolecules for clients. “The RIA method is used for the determination of several pharmaceutically important compounds in biological fluids. RIA requires a sample containing the antigen of interest, a complementary antibody, and a radiolabelled version of the antigen. To increase the selectivity of an assay, all samples are pre-treated to eliminate high molecular weight endogenous matrix components, including anti-drug antibodies,” explains Engelbrecht.

Although FARMOVS has adequate technology to provide market-related results, the plan is to expand the team to include a multiplex platform that is a sensitive, fully automated immunoassay platform with multiplexing and custom assay capability. “This will pave the way to use an even more sensitive method to quantify biomarkers in the fields of oncology, neurology, cardiology, inflammation, and infectious disease. We aim to remain competitive in our industry, so naturally we must recruit the brightest and most evolved to join the team,” he says.

News Archive

Link between champagne bubbles and the UFS?
2012-11-16

Prof. Lodewyk Kock with an example of a front page of the publication FEMS Yeast Research, as adapted by F. Belliard, FEMS Central Office.
Photo: Leatitia Pienaar
15 November 2012

What is the link between the bubbles in champagne and breakthrough research being done at the Mayo Clinic in America? Nano research being done at our university.

Prof. Lodewyk Kock of Biotechnology says a human being consists of millions of minute cells that are invisible to the eye. The nano technology team at the UFS have developed a technique that allows researchers to look into such a cell, as well as other microorganisms. In this way, they can get an idea of what the cell’s “insides” look like.

The UFS team – consisting of Profs. Kock, Hendrik Swart (Physics), Pieter van Wyk (Centre for Microscopy), as well as Dr Chantel Swart (Biotechnology), Dr Carlien Pohl (Biotechnology) and Liza Coetsee (Physics) – were amazed to see that the inside of cells consist of a maze of small tunnels or blisters. Each tunnel is about 100 and more nanometres in diameter – about one ten thousandth of a millimetre – that weaves through the cells in a maze.

It was also found that these tunnels are the “lungs” of the cells. Academics doing research on yeast have had to sit up and take notice of the research being done at the UFS – to the extent that these “lungs” will appear on the front page of the highly acclaimed FEMS Yeast Research for all of 2013.

The Mayo Clinic, in particular, now wants to work with the UFS to study cancer cells in more detail in order to fight this disease, says Prof. Kock. The National Cancer Institute of America has also shown interest. This new nano technology for biology can assist in the study and development of nano medicine that can be used in the treatment of cancer and other life threatening diseases. Nano medicine uses nano metal participles that are up to one billionth of a metre in size.

Prof. Kock says laboratory tests indicate that nano medicine can improve the efficacy of anti-cancer medicine, which makes the treatment less toxic. “According to the Mayo Clinic team, nano particles are considered as a gold cartridge which is being fired directly at a cancer tumour. This is compared to fine shot that spreads through the body and also attacks healthy cells.”

“This accuracy implies that the chemotherapy dose can be lowered with fewer side effects. The Mayo Clinic found that one-tenth of the normal dosage is more effective against pancreas cancer in this way than the full dosage with a linkage to nano particles. According to the clinic, this nano medicine could also delay the spread of cancer,” says Prof. Kock.

The nano particles are used as messengers that convey anti-cancer treatment to cancer cells, where it then selectively kills the cancer cells. The transport and transfer of these medicines with regard to gold nano particles can be traced with the UFS’s nano technology to collect more information, especially where it works on the cell.

“With the new nano technology of the UFS, it is possible to do nano surgery on the cells by slicing the cells in nanometre thin slices while the working of the nano medicine is studied. In this way, it can be established if the nano medicine penetrates the cells or if it is only associated with the tiny tunnels,” says Prof. Kock.

And in champagne the small “lungs” are responsible for the bubbles. The same applies to beer and with this discovery a whole new reach field opens for scientists.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept